A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic Pemphigus (Vulgaris or Foliaceus)

Trial Profile

A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic Pemphigus (Vulgaris or Foliaceus)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2017

At a glance

  • Drugs SYNT 001 (Primary)
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions
  • Sponsors Syntimmune
  • Most Recent Events

    • 01 Nov 2017 According to a Syntimmune media release, topline data from this trial is expected in the first half of 2018.
    • 14 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 14 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top